Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety
Aim. To compare safety of new class III antiarrhythmic drug Refralon with direct current cardioversion (DCC) in patients with persistent atrial fibrillation (AF). Material and methods. 60 patients with persistent AF were randomized to groups of DCC (n=30) and pharmacologic conversion (PCV; n=30). Th...
Saved in:
| Main Authors: | N. Yu. Mironov, V. V. Vlodzyanovskiy, Yu. A. Yuricheva, S. F. Sokolov, S. P. Golitsyn, L. V. Rosenstraukh, E. I. Chazov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2019-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1794 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness
by: N. Yu. Mironov, et al.
Published: (2018-11-01) -
Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
by: Kh. M. Dzaurova, et al.
Published: (2025-06-01) -
PAROXYSMAL ATRIAL FIBRILLATION: CHOICE OF CARDIOVERSION THERAPY
by: B. A. Tatarskii
Published: (2015-12-01) -
Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01) -
Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety
by: N. Yu. Mironov, et al.
Published: (2021-11-01)